| Literature DB >> 27547674 |
Horacio Pérez-Sánchez1, Vahid Rezaei2, Vitaliy Mezhuyev3, Duhu Man4, Jorge Peña-García1, Helena den-Haan1, Sandra Gesing5.
Abstract
BACKGROUND: Methods for in silico screening of large databases of molecules increasingly complement and replace experimental techniques to discover novel compounds to combat diseases. As these techniques become more complex and computationally costly we are faced with an increasing problem to provide the research community of life sciences with a convenient tool for high-throughput virtual screening on distributed computing resources.Entities:
Keywords: Drug discovery; FlexScreen; High performance computing; Science gateways; Virtual screening
Year: 2016 PMID: 27547674 PMCID: PMC4978646 DOI: 10.1186/s40064-016-2914-x
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Fig. 1Integration of FlexScreen into Pipeline Pilot workflows. Pipelines 1 and 2 read and format the ligand database and receptor files. In Pipeline 3 the input molecules are received and the docking simulation parameters are specified. Then the FlexScreen component performs the SOAP calls and runs the calculations on the HPC resources. Finally the results are processed and presented in an interactive table format
Fig. 2Architecture of the implemented FlexScreen module (cf. Fig. 1). This figure represents the case of use of distributed HPC resources via a SOAP client–server pair
Fig. 3Sample of the output results in HTML format directly from the web browser. HTVS results are presented in consecutive rows for the different ligands of the database. Different columns contain information about each ligand regarding name, energy calculations, RMSD, etc. Clicking on each ligand 2D representation opens a new window with detailed information about the 3D ligand-binding mode as shown in Fig. 4
Fig. 43D representation of the HTVS results obtained for two different receptor–ligand pairs. Blue color denotes the experimental ligand binding mode, orange color the FlexScreen prediction without considering solvation, and the red color the prediction with the consideration of solvation. a Factor Xa in complex with 1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3- ylmethyl]-3-cyano-7-methyl-1h-indole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide. b Thrombin in complex with 6-chloro-2-(2-hydroxy-biphenyl-3-yl)-1h-indole-5-carboxamidine